Idt Australia Limited · ASX:IDT
Idt Australia — FY2024 Earnings Presentation
16 slides from Idt Australia's earnings presentation, Aug 26, 2024
Slide 1: IDT Australia FY24 Full Year Results
For personal use only IDT Australia FY24 Full Year Results
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not
Slide 3: IDT Overview
IDT Overview Year of Innovation in Drug Design & Manufacture For personal use only 50 Years of Operational Excellence with 30 Novel Chemical Entities Returning to Profitability ▪ Growth accelerating and expanding pipeline of potential sales opportunities ▪ Operating leverage as business scales with
Slide 4: FY24 Result Highlights
FY24 Result Highlights Further Achievements in 2nd Year of Strategic Pivot For personal use only Doubling of Revenue in FY24 vs. FY23 '000 $16,000 $14,000 Disbursements/Others Accelerating Growth: Operating Revenue +91.1% YoY to $12.3M and $12,000 Statutory Revenue +100.8% to $14.1M $10,000 Advanced
Slide 5: Growth Accelerating
Growth Accelerating Quarterly Revenue Performance For personal use only Quarterly Revenue FY23 to FY24 $5 Millions API Manufacturing Speciality Orals Advanced Therapies Disbursements / Others $4 $3 $2 $1 $0 1QFY23 2QFY23 3QFY23 4QFY23 1QFY24 2QFY24 3QFY24 4QFY24 Step-up in the pace of revenue growth
Slide 6: Core Pillars
Core Pillars High Growth Opportunities For personal use only Active Pharmaceutical Ingredients Specialty Orals Advanced Therapies 40.4% of Total FY24 Revenue 39.7% of Total FY24 Revenue 12.5% of Total FY24 Revenue • IDT’s original business • Tablet, capsules and liquid orals • High value platforms i
Slide 7: API Performance +227%
API Performance +227% REVENUE Quantum Jump over FY23 Active Pharmaceutical Ingredients (API) For personal use only '000 $6,000 REVENUE DRIVERS $5,000 Up 227% YoY to Primarily due to $5.5M & +395% larger repeat over two years orders & new $4,000 psychedelic clients $3,000 $2,000 SYNERGY EDGE Compleme
Slide 8: Addressable Market for API
Addressable Market for API Leveraged to Multiple Lucrative Opportunities For personal use only $250B $199B $18M TAM SAM SOM Global market forecast to hit Forecast to reach ~US$199B by 2026, Estimated using current site capacity US$250B by 2026 (6.4% CAGR)1 representing part of the TAM that can be on
Slide 9: Specialty Orals +20%
Specialty Orals +20% REVENUE Overcoming Challenging Market Speciality Orals (SO) '000 For personal use only $6,000 REVENUE DRIVERS $5,000 Up 20% YoY to Growth largely $5.4M despite due to $4,000 challenging integration with medcan market API vertical $3,000 $2,000 SKEW TAILWINDS $1,000 Medcan +18% L
Slide 10: Addressable Market for SO
Addressable Market for SO Medical Cannabis & Psychedelics For personal use only $64B $57B $72M TAM SAM SOM Global market forecast to hit Forecast to reach ~US$57B by 2026, Estimated using current on-site capacity at US$64B by 2026 (18.1% CAGR)1,2 representing part of the TAM that can ~$US72M by 2026
Slide 11: Advanced Therapies Key Growth Engine +415%
Advanced Therapies Key Growth Engine +415% REVENUE '000 Advanced Therapies (AT) $1,600 For personal use only $1,400 REVENUE Up 415% YoY to DRIVERS $1,200 Emerging ADC $1.4M after and mRNA securing a sterile $1,000 technologies are licence driving demand extension in Apr $800 2023 $600 $400 CLIENTS L
Slide 12: Victorian Government Grant
Victorian Government Grant Australia’s 1st Commercial ADC Facility For personal use only Victorian Government will partially The $3.8M cGMP facility targets the fund, design, fit out and equip the US$140B global ADC market* ADC facility Australia will have the ability to make ADCs are smart drugs th
Slide 13: Addressable Market for AT
Addressable Market for AT Aseptic Fill & Finish (ADC & mRNA) For personal use only $13.1B $3.4B $805M TAM SAM SOM Global market forecast to hit Forecast to reach ~US$3.4B by 2026, Estimated using on-site capacity and future US$13.1B by 2026 (22% CAGR)1 representing part of the TAM that can capacity
Slide 14: Outlook & Summary
Outlook & Summary Drivers in FY25 and Beyond For personal use only 50 Years of Operational Excellence with 30 Novel Chemical Entities Positive Outlook Global Tailwinds Strong momentum into FY25 & growing sales pipeline with Growing demand for mRNA, ADC, mental disorder treatments & further improveme
Slide 15: Glossary / Acronym Meanings
Our A D C Antibody Drug Conjugate m R N A Messenger Ribonucleic Acid For personal use only Glossary A P I Active Pharmaceutical Ingredient M D M A Methylene-dioxy-meth-amphetamine A S P Aseptic Sterile Processing O D C Office of Drug Control Acronym c G M P Current Good Manufacturing Practice P T S
Slide 16: IDT Australia Investor & Media Enquiries
For personal use only IDT Australia Investor & Media Enquiries: Brendon Lau e: brendon@vantagepointpartners.com.au IDT Australia FY24 Results m: 0409 341 613